Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Jul;68(1):18–25. doi: 10.1038/bjc.1993.280

Melphalan sensitivity as a function of progressive metastatic growth in two subpopulations of a mouse mammary tumour.

B E Miller 1, F R Miller 1, T Machemer 1, G H Heppner 1
PMCID: PMC1968286  PMID: 8318410

Abstract

In order to examine in detail the sensitivity to chemotherapy of tumour cells at various organ sites and at various stages of metastasis, we have used a series of cell lines, all selected from sister subpopulations derived from a single mouse mammary tumour, which can be distinguished and quantitated from normal cells and from each other through growth in selective medium. For the studies described here, we used two lines, 4T07 and 66FAR, which will form colonies in vitro in medium containing 60 microM 6-thioguanine or 330 microM 2,6-diaminopurine, respectively. Both cell lines have similar sensitivity to the test chemotherapeutic agent, melphalan, in vitro. These two tumour cell lines were treated with melphalan in vivo, when growing either in lungs as experimental metastases at various times after cell injection or as palpable tumours growing subcutaneously. Responses to various doses of melphalan were measured by removing lungs or subcutaneous tumours and performing colony-forming assays in selective medium. The data indicate marked shifts in sensitivity as a function of metastatic stage. Analyses of dose-response curves show that both cell lines were similarly sensitive to melphalan at early times (45 min) after cell injection i.v. but became less sensitive at an intermediate time after injection (3 days). Differences between the two lines became apparent at later times after i.v. injection (by day 8 or 9) and in subcutaneous tumours, where a marked reduction in the shoulder of the dose response curve was seen in line 4T07, resulting in sensitivity equal to or greater than the of early times, whereas the dose response parameters of 66FAR remained at those of the intermediate time point. These results show that, in heterogeneous tumours, individual subpopulations of tumour cells may respond differently to chemotherapeutic agents at various disease stages. In vitro measures of tumour sensitivity do not predict these changes in in vivo sensitivity. Model systems similar to the one described here may yield information which will eventually be useful in maximising the efficacy of clinically relevant adjuvant chemotherapy regimens.

Full text

PDF
18

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aslakson C. J., McEachern D., Conaway D. H., Miller F. R. Inhibition of lung colonization at two different steps in the metastatic sequence. Clin Exp Metastasis. 1991 Mar-Apr;9(2):139–150. doi: 10.1007/BF01756385. [DOI] [PubMed] [Google Scholar]
  2. Aslakson C. J., Rak J. W., Miller B. E., Miller F. R. Differential influence of organ site on three subpopulations of a single mouse mammary tumor at two distinct steps in metastasis. Int J Cancer. 1991 Feb 1;47(3):466–472. doi: 10.1002/ijc.2910470327. [DOI] [PubMed] [Google Scholar]
  3. Bhuyan B. K., Scheidt L. G., Fraser T. J. Cell cycle phase specificity of antitumor agents. Cancer Res. 1972 Feb;32(2):398–407. [PubMed] [Google Scholar]
  4. Blosmanis R., Wright J. A., Goldenberg G. J. Sensitivity to melphalan as a function of transport activity and proliferative rate in BALB/c 3T3 fibroblasts. Cancer Res. 1987 Mar 1;47(5):1273–1277. [PubMed] [Google Scholar]
  5. Dexter D. L., Kowalski H. M., Blazar B. A., Fligiel Z., Vogel R., Heppner G. H. Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res. 1978 Oct;38(10):3174–3181. [PubMed] [Google Scholar]
  6. Fidler I. J. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res. 1978 Sep;38(9):2651–2660. [PubMed] [Google Scholar]
  7. Frei E., 3rd, Teicher B. A., Holden S. A., Cathcart K. N., Wang Y. Y. Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res. 1988 Nov 15;48(22):6417–6423. [PubMed] [Google Scholar]
  8. Heppner G. H., Dexter D. L., DeNucci T., Miller F. R., Calabresi P. Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor. Cancer Res. 1978 Nov;38(11 Pt 1):3758–3763. [PubMed] [Google Scholar]
  9. Liotta L. A., DeLisi C. Method for quantitating tumor cell removal and tumor cell-invasive capacity in experimental metastases. Cancer Res. 1977 Nov;37(11):4003–4008. [PubMed] [Google Scholar]
  10. Miller B. E., Aslakson C. J., Miller F. R. Efficient recovery of clonogenic stem cells from solid tumors and occult metastatic deposits. Invasion Metastasis. 1990;10(2):101–112. [PubMed] [Google Scholar]
  11. Miller B. E., Machemer T., Lehotan M., Heppner G. H. Tumor subpopulation interactions affecting melphalan sensitivity in palpable mouse mammary tumors. Cancer Res. 1991 Aug 15;51(16):4378–4387. [PubMed] [Google Scholar]
  12. Miller B. E., Miller F. R., Heppner G. H. Therapeutic perturbation of the tumor ecosystem in reconstructed heterogeneous mouse mammary tumors. Cancer Res. 1989 Jul 15;49(14):3747–3753. [PubMed] [Google Scholar]
  13. Miller B. E., Miller F. R., Wilburn D. J., Heppner G. H. Analysis of tumour cell composition in tumours composed of paired mixtures of mammary tumour cell lines. Br J Cancer. 1987 Nov;56(5):561–569. doi: 10.1038/bjc.1987.242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Miller F. R., Miller B. E., Heppner G. H. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis. 1983;3(1):22–31. [PubMed] [Google Scholar]
  15. Parsons P. G., Carter F. B., Morrison L., Regius Mary Sister Mechanism of melphalan resistance developed in vitro in human melanoma cells. Cancer Res. 1981 Apr;41(4):1525–1534. [PubMed] [Google Scholar]
  16. Parsons P. G. Dependence on treatment time of melphalan resistance and DNA cross-linking in human melanoma cell lines. Cancer Res. 1984 Jul;44(7):2773–2778. [PubMed] [Google Scholar]
  17. Schmid F. A., Otter G. M., Stock C. C. Resistance patterns of Walker carcinosarcoma 256 and other rodent tumors to cyclophosphamide and L-phenylalanine mustard. Cancer Res. 1980 Mar;40(3):830–833. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES